A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer (NCT07644559)
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
🩺 Plain-English Summary (8th-Grade Level)
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Who can join: Review the eligibility criteria below.
Location: START- Los Angeles — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- START- Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Mayo Clinical Florida — Jacksonville, Florida
- Moffitt Cancer Center — Tampa, Florida
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- START Midwest — Grand Rapids, Michigan
- Mayo Clinical Rochester — Rochester, Minnesota
- Washington University — St Louis, Missouri
- START New Jersey — East Brunswick, New Jersey
- NYU-Manhattan — New York, New York
- University of North Carolina — Chapel Hill, North Carolina
- Sarah Cannon Research Institute — Nashville, Tennessee
- START Dallas — Fort Worth, Texas
- MD Anderson Cancer Center — Houston, Texas
- START- San Antonio — San Antonio, Texas
- START- Mountain Region — West Valley City, Utah
- UVA Health — Charlottesville, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Mason — Seattle, Washington
- UW Health — Madison, Wisconsin
- Macquarie University Hospital — Sydney, New South Wales
📞 Contact the Study Coordinator
Phone: (781) 292-4204
Email: VS-7375-201TrialSupport@verastem.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Ductal Adenocarcinoma (PDAC)
- Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial — Boston, Massachusetts
- Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life — Vancouver, British Columbia
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) — Burlington, Vermont
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) — Birmingham, Alabama
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer — La Jolla, California
Explore by condition: All Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.